$2.41
0.41% day before yesterday
Nasdaq, Dec 27, 10:17 pm CET
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Nkarta Inc Stock price

$2.41
-0.58 19.40% 1M
-3.45 58.87% 6M
-4.19 63.48% YTD
-2.96 55.12% 1Y
-12.78 84.13% 3Y
-45.49 94.97% 5Y
-45.49 94.97% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.01 0.41%
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Key metrics

Market capitalization $170.07m
Enterprise Value $-27.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.25
P/B ratio (TTM) P/B ratio 0.39
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-128.46m
Free Cash Flow (TTM) Free Cash Flow $-108.41m
Cash position $283.06m
EPS (TTM) EPS $-1.87
P/E forward negative
Short interest 12.49%
Show more

Is Nkarta Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Nkarta Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Nkarta Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Nkarta Inc forecast:

Buy
100%

Financial data from Nkarta Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 9.12 9.12
37% 37%
-
-9.12 -9.12
37% 37%
-
- Selling and Administrative Expenses 22 22
14% 14%
-
- Research and Development Expense 88 88
8% 8%
-
-119 -119
7% 7%
-
- Depreciation and Amortization 9.12 9.12
37% 37%
-
EBIT (Operating Income) EBIT -128 -128
5% 5%
-
Net Profit -111 -111
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nkarta Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nkarta Inc Stock News

Neutral
GlobeNewsWire
24 days ago
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Neutral
GlobeNewsWire
about 2 months ago
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
More Nkarta Inc News

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Paul Hastings
Employees 150
Founded 2005
Website www.nkartatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today